StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HCA$373.55-1.32%
Fair $373.55+0.0%

HCA

HCA Healthcare, Inc.

Healthcare / Medical Care FacilitiesNYSE

$373.55

-4.99 (-1.32%)

Fairly Valued+0.0%Fair Value $373.55Fund rank 38/100 · Data gapFallback financials|
SA 45/C
F-Score: 7/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 22% · confianza 25%

FCF escenarios

weak_data · normalized FCF $5.6B · quality 81.7/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 82/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 17Warnings: 1unknown: 17
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.1%, below the 5% threshold
Thesis & Journal · HCALocal privado en este navegador · HCA Healthcare, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$82.9B

P/E

12.9x

↓

EV/EBITDA

8.8x

↓

ROE

-112.6%

↓

Gross Margin

41.5%

↓

Debt/Equity

-8.08

↓
52-Week Range$374
$330$557

TradingView lightweight chart

HCA price, volumen y niveles de valoración

Último $373.55Periodo +1104.2%
Fair value: $373.55

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2009–2025 · 16 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

+11.1%

FCF margin

10.2%

FCF / Net income

1.13x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $75.60B · net income $6.78B · FCF $7.69B

2009-FY → 2025-FY

Gross margin

41.5%— pts

Operating margin

15.8%— pts

Net margin

9.0%— pts

FCF margin

10.2%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Income Statement
Revenue$75.60B$75.60B$70.60B$64.97B$60.23B$58.75B$51.53B$51.34B——————————
Net Income$6.78B$6.78B$5.76B$5.24B$5.64B$6.96B$3.75B$3.50B$3.79B$2.22B$2.89B$2.13B$1.88B$1.56B$1.60B$2.46B$1.21B$1.05B
EBITDA$15.60B$15.60B$13.90B$12.72B$13.29B—————————————
EPS28.3328.3322.0018.9719.1521.1610.9310.0710.665.957.304.994.163.373.494.972.762.44
Gross Margin41.5%41.5%40.6%39.4%38.5%—————————————
Operating Margin15.8%15.8%14.9%14.8%15.0%—————————————
Net Margin9.0%9.0%8.2%8.1%9.4%11.8%7.3%6.8%——————————
Balance Sheet
Debt/Equity-8.08-8.08-18.10-23.60-14.53-36.8153.84-11.96-6.47-4.83-4.27-3.98-3.68-3.34-2.85-3.112.32—
Current Ratio0.830.83————————————————
Cash Flow
Free Cash Flow$7.69B$7.69B$5.64B$4.69B$4.13B$5.38B$6.40B$3.44B$3.19B$2.41B$2.89B—$2.27B$1.74B$2.31B$2.25B$1.76B$1.43B
Returns
ROE-112.6%-112.6%-230.5%-295.5%-203.9%-745.6%656.3%-124.8%-76.5%-32.6%-39.6%-28.0%-23.8%-18.8%-16.6%-29.8%10.1%—
Valuation
P/E12.8712.8713.4914.5413.29—————————————
EV/EBITDA8.798.798.719.218.60—————————————
Growth & Yield
Revenue Growth7.1%7.1%8.7%7.9%—14.0%0.4%———————————
EPS Growth28.8%28.8%16.0%-0.9%—93.6%8.5%-5.5%79.2%-18.5%46.3%20.0%23.4%-3.4%-29.8%80.1%13.1%—
Dividend Yield0.8%0.8%————————————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

5.4%

razonable

EPS terminal req.

$33.15

Spread vs growth

23.4%

5Y implied EPS CAGR

7.2%

razonable

EPS terminal req.

$40.11

Spread vs growth

21.6%

10Y implied EPS CAGR

8.6%

razonable

EPS terminal req.

$64.59

Spread vs growth

20.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -1.2%

Total return

-1.2%

Start / end P/E

17.3x → 13.2x

EPS bridge

22.00 → 28.33

Residual

-6.9%

EPS growth+28.8%
Multiple rerating-23.9%
Dividend+0.8%
Residual / FX / buybacks / cross-term-6.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.